Quizartinib
- Generic Name
- Quizartinib
- Brand Names
- Vanflyta
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32N6O4S
- CAS Number
- 950769-58-1
- Unique Ingredient Identifier
- 7LA4O6Q0D3
- Background
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
- Indication
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-appr...
- Associated Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Associated Therapies
- -
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT06740825
- Locations
- 🇺🇸
WCT, San Antonio, Texas, United States
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT06740799
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
🇺🇸GCP Research, Saint Petersburg, Florida, United States
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 700
- Registration Number
- NCT06578247
- Locations
- 🇺🇸
City of Hope Phoenix, Goodyear, Arizona, United States
🇺🇸Mayo Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
- Conditions
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 84
- Registration Number
- NCT04687761
- Locations
- 🇪🇸
Hospital Universitario PrÃncipe de Asturias, Alcalá De Henares, Spain
🇪🇸Hospital ClÃnic, Barcelona, Spain
🇪🇸Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- University Hospital Heidelberg
- Registration Number
- NCT04676243
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT04493138
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
- Conditions
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT04473664
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04459598
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04459585
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.